Published in Int J Cancer on November 10, 2004
Reversibility of regorafenib effects in hepatocellular carcinoma cells. Cancer Chemother Pharmacol (2013) 0.86
Synthesis and Antitumor Activity Evaluation of a Novel Combi-nitrosourea Prodrug: BGCNU. ACS Med Chem Lett (2017) 0.75
Characterization of the potency of epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain. Invest New Drugs (2010) 0.75
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res (2007) 1.90
The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem (2003) 1.56
Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol (2009) 1.37
Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem (2003) 1.34
TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells. Breast Cancer Res (2008) 1.11
HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells. Oncogene (2005) 1.07
Phosphorylated Pak1 level in the cytoplasm correlates with shorter survival time in patients with glioblastoma. Clin Cancer Res (2007) 1.06
Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discovery of an unusual structure-activity relationship. J Med Chem (2007) 1.01
Flow cytometric analysis of micronuclei in peripheral blood reticulocytes: II. An efficient method of monitoring chromosomal damage in the rat. Toxicol Sci (2006) 1.01
Programmed cell death 4 inhibits breast cancer cell invasion by increasing tissue inhibitor of metalloproteinases-2 expression. Breast Cancer Res Treat (2008) 0.99
all-trans-Retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukemia. Am J Hematol (2002) 0.96
JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells. Int J Oncol (2011) 0.96
Interlaboratory validation of a CD71-based flow cytometric method (Microflow) for the scoring of micronucleated reticulocytes in mouse peripheral blood. Environ Mol Mutagen (2005) 0.95
Leptin utilizes Jun N-terminal kinases to stimulate the invasion of MCF-7 breast cancer cells. Clin Exp Metastasis (2008) 0.92
Downregulation of Wilms' tumor 1 protein inhibits breast cancer proliferation. Biochem Biophys Res Commun (2002) 0.91
The potential of drug-carrying immunoliposomes as anticancer agents. Commentary re: J. W. Park et al., Anti-HER2 immunoliposomes: enhanced efficacy due to targeted delivery. Clin. Cancer Res., 8: 1172-1181, 2002. Clin Cancer Res (2002) 0.91
Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cells. Lab Invest (2005) 0.89
Cyclooxygenase-2 is essential for HER2/neu to suppress N- (4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells. Cancer Res (2004) 0.89
Cyclooxygenase-2 uses the protein kinase C/ interleukin-8/urokinase-type plasminogen activator pathway to increase the invasiveness of breast cancer cells. Int J Oncol (2007) 0.89
Cylindrical waveguide electromagnetic exposure system for biological studies with unrestrained mice at 1.9 GHz. Health Phys (2012) 0.87
Synthesis, characterization and anticancer studies of mixed ligand dithiocarbamate palladium(II) complexes. Eur J Med Chem (2011) 0.87
Inhibition of cell signaling by the combi-nitrosourea FD137 in the androgen independent DU145 prostate cancer cell line. Prostate (2004) 0.85
A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxide. Mol Cancer Ther (2002) 0.85
Fractionated X-radiation treatment can elicit an inducible-like radioprotective response that is not dependent on the intrinsic cellular X-radiation resistance/sensitivity. Radiat Res (2006) 0.85
N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells. Carcinogenesis (2005) 0.85
Flow cytometric analysis of micronuclei in peripheral blood reticulocytes: I. Intra- and interlaboratory comparison with microscopic scoring. Toxicol Sci (2006) 0.84
N-(4-Hydroxyphenyl)retinamide and nitric oxide pro-drugs exhibit apoptotic and anti-invasive effects against bone metastatic breast cancer cells. Carcinogenesis (2005) 0.84
The combi-targeting concept: in vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive. Clin Cancer Res (2007) 0.83
The genotoxicity of mainstream and sidestream marijuana and tobacco smoke condensates. Chem Res Toxicol (2009) 0.83
Analysis of proto-oncogene and heat-shock protein gene expression in human derived cell-lines exposed in vitro to an intermittent 1.9 GHz pulse-modulated radiofrequency field. Int J Radiat Biol (2006) 0.83
The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo. J Pharmacol Exp Ther (2004) 0.83
Recent advances in research on radiofrequency fields and health: 2004-2007. J Toxicol Environ Health B Crit Rev (2009) 0.82
KGF-induced motility of breast cancer cells is dependent on Grb2 and Erk1,2. Clin Exp Metastasis (2004) 0.82
Optimization of novel combi-molecules: identification of balanced and mixed bcr-abl/DNA targeting properties. Bioorg Med Chem Lett (2007) 0.82
"Combi-targeting" mitozolomide: conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer. Prostate (2012) 0.82
Molecular analysis of the in vivo metabolism and biodistribution of metabolically and non-metabolically activated combi-molecules of the triazene class. Drug Metab Lett (2009) 0.82
Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting concept. J Med Chem (2003) 0.82
Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species. Mol Cancer Ther (2010) 0.81
Cellular pharmacology of P-ethoxy antisense oligonucleotides targeted to Bcl-2 in a follicular lymphoma cell line. Leuk Lymphoma (2003) 0.81
Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda. Breast Cancer Res Treat (2011) 0.81
Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer. Mol Cancer Ther (2010) 0.81
The combi-targeting concept: chemical dissection of the dual targeting properties of a series of "combi-triazenes". J Med Chem (2003) 0.81
Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency. Biochem Pharmacol (2005) 0.81
Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41. Cancer Chemother Pharmacol (2002) 0.80
Nuclear retinoid receptors are involved in N-(4-hydroxyphenyl) retinamide (Fenretinide)-induced gene expression and growth inhibition in HL-60 acute myeloid leukemia cells. Leuk Lymphoma (2004) 0.80
Protection from solar simulated radiation-induced DNA damage in cultured human fibroblasts by three commercially available sunscreens. Can J Physiol Pharmacol (2003) 0.80
Use of the comet assay in environmental toxicology. Methods Mol Biol (2008) 0.80
Assessment of genetic damage in peripheral blood of human volunteers exposed (whole-body) to a 200 muT, 60 Hz magnetic field. Int J Radiat Biol (2009) 0.80
Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for Combi-Targeting postulates. J Pharmacol Exp Ther (2002) 0.80
Bcl-2-related antisense therapy. Semin Oncol (2002) 0.80
The combi-targeting concept: evidence for the formation of a novel inhibitor in vivo. Anticancer Drugs (2006) 0.79
MGMT is a molecular determinant for potency of the DNA-EGFR-combi-molecule ZRS1. Mol Cancer Res (2011) 0.79
Synthesis of water soluble bis-triazenoquinazolines: an unusual predicted mode of binding to the epidermal growth factor receptor tyrosine kinase. Chem Biol Drug Des (2008) 0.79
Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells. Breast Cancer Res (2007) 0.79
Effects of alpha particle radiation on gene expression in human pulmonary epithelial cells. Int J Hyg Environ Health (2012) 0.79
Biological effects of alpha particle radiation exposure on human monocytic cells. Int J Hyg Environ Health (2011) 0.79
The combi-targetinG concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA targeting "combi-triazene" SMA41. Biochem Pharmacol (2004) 0.78
Stability of 5-acetamido-6-formylamino-3-methyluracil in buffers and urine. J Pharm Biomed Anal (2002) 0.78
The Concept of Divergent Targeting through the Activation and Inhibition of Receptors as a Novel Chemotherapeutic Strategy: Signaling Responses to Strong DNA-Reactive Combinatorial Mimicries. J Signal Transduct (2012) 0.78
The combi-targeting concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properties. Cancer Chemother Pharmacol (2002) 0.78
Analysis of gene expression in two human-derived cell lines exposed in vitro to a 1.9 GHz pulse-modulated radiofrequency field. Proteomics (2007) 0.78
The HER2/Grb2/Akt pathway regulates the DNA binding activity of AP-1 in breast cancer cells. Oncol Rep (2004) 0.78
Antineoplastic Activity of New Transition Metal Complexes of 6-Methylpyridine-2-carbaldehyde-N(4)-ethylthiosemicarbazone: X-Ray Crystal Structures of [VO(2)(mpETSC)] and [Pt(mpETSC)Cl]. Bioinorg Chem Appl (2010) 0.78
Engineering 3-alkyltriazenes to block bcr-abl kinase: a novel strategy for the therapy of advanced bcr-abl expressing leukemias. Leuk Res (2005) 0.78
Type II combi-molecules: design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05. Anticancer Drugs (2007) 0.77
The combi-targeting concept: selective targeting of the epidermal growth factor receptor- and Her2-expressing cancer cells by the complex combi-molecule RB24. J Pharmacol Exp Ther (2010) 0.77
Liposomal antisense oligonucleotides for cancer therapy. Methods Enzymol (2004) 0.77
Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia. Mol Cancer Ther (2008) 0.77
Dosimetry evaluation of a cylindrical waveguide chamber for unrestrained small rodents at 1.9 GHz. Bioelectromagnetics (2012) 0.77
Programmed cell death 4 inhibits leptin-induced breast cancer cell invasion. Oncol Rep (2011) 0.77
Use of comet and micronucleus assays to measure genotoxicity in meadow voles (Microtus pennsylvanicus) living in golf course ecosystems exposed to pesticides. Ecotoxicology (2005) 0.77
N-(4-hydroxyphenyl)-retinamide selectively increases All-TRANS retinoic acid inhibitory effects in HER2/NEU-overexpressing breast cancer cells. Tumour Biol (2003) 0.77